Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)

• Phase III study comparing Trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory s … Recruiting
  2024-516392-33-00 5 2021-09-17

Showing 1–1 of 1 trials